Journal Article

Artificial intelligence-based preventive, personalized and precision medicine for cardiovascular disease/stroke risk assessment in rheumatoid arthritis patients: a narrative review

Saba, Luca, Suri, Jasjit S, Al-Maini, Mustafa, Isenovic, Esma R, Miner, Martin, Sharma, Aman, Rathore, Vijay, Mavrogeni, Sophie, Agarwal, Vikas, Khanna, Narendra N, Johri, Amer M, Mantella, Laura, Teji, Jagjit, Viskovic, Klaudija, Singh, Inder M, Tsoulfas, George, Misra, Durga Prasanna, Turk, Monika, Kalra, Manudeep K, Fouda, Mostafa M, Maindarkar, Mahesh, Ruzsa, Zoltan, Faa, Gavino, Laird, John R, Kitas, George D

2023

Overview

The challenges associated with diagnosing and treating cardiovascular disease (CVD)/Stroke in Rheumatoid arthritis (RA) arise from the delayed onset of symptoms. Existing clinical risk scores are inadequate in predicting cardiac events, and conventional risk factors alone do not accurately classify many individuals at risk. Several CVD biomarkers consider the multiple pathways involved in the development of atherosclerosis, which is the primary cause of CVD/Stroke in RA. To enhance the accuracy of CVD/Stroke risk assessment in the RA framework, a proposed approach involves combining genomic-based biomarkers (GBBM) derived from plasma and/or serum samples with innovative non-invasive radiomic-based biomarkers (RBBM), such as measurements of synovial fluid, plaque area, and plaque burden. This review presents two hypotheses: (i) RBBM and GBBM biomarkers exhibit a significant correlation and can precisely detect the severity of CVD/Stroke in RA patients. (ii) Artificial Intelligence (AI)-based preventive, precision, and personalized (aiP3) CVD/Stroke risk AtheroEdge™ model (AtheroPoint™, CA, USA) that utilizes deep learning (DL) to accurately classify the risk of CVD/stroke in RA framework. The authors conducted a comprehensive search using the PRISMA technique, identifying 153 studies that assessed the features/biomarkers of RBBM and GBBM for CVD/Stroke. The study demonstrates how DL models can be integrated into the AtheroEdge™–aiP3 framework to determine the risk of CVD/Stroke in RA patients. The findings of this review suggest that the combination of RBBM with GBBM introduces a new dimension to the assessment of CVD/Stroke risk in the RA framework. Synovial fluid levels that are higher than normal lead to an increase in the plaque burden. Additionally, the review provides recommendations for novel, unbiased, and pruned DL algorithms that can predict CVD/Stroke risk within a RA framework that is preventive, precise, and personalized.

• Publisher: Springer Nature B.V
• Subject: Artificial intelligence / Biomarkers / Cardiovascular disease / Rheumatoid arthritis / Risk assessment / Stroke